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Venetoclax for Treating Chronic Lymphocytic Leukaemia:
An Evidence Review Group Perspective of a NICE Single
Technology Appraisal
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Theodoros Mantopoulos1 • Emma Loveman2 • Renata Walewska3 •
James Mason1
 The Author(s) 2017. This article is an open access publication
Abstract Venetoclax is licensed to treat relapsed or
refractory (R/R) chronic lymphocytic leukaemia (CLL). As
part of the Single Technology Appraisal (STA) ID944, the
National Institute for Health and Care Excellence (NICE)
invited AbbVie, the manufacturer, to submit evidence on
the use of venetoclax, within its licensed indication. The
Evidence Review Group (ERG), Warwick Evidence, was
asked to provide an independent and critical review of the
submitted evidence. Evidence came from three single-arm
trials in CLL patients with or without 17p deletion
[del(17p])/TP53 chromosomal abnormalities. The antici-
pated licensed indication specified that venetoclax-eligible
del(17p)/TP53 patients should have not responded to, or be
deemed unsuitable for, B-cell receptor inhibitor (BCRi)
therapy, and that non-del(17p)/TP53 patients should have
not responded to both chemoimmunotherapy and BCRi
therapy. The three trials were heterogeneous in terms of
both del(17p)/TP53 status and previous exposure to BCRi
therapy. The M13-982 study investigated 158 R/R CLL
patients with the 17p deletion, but only a small number had
received previous BCRi therapy; the M12-175 study
investigated 67 patients with CLL or small lymphocytic
lymphoma, some with the 17p deletion, but very few pre-
viously treated with BCRi therapy; and the M14-032 study
included 105 patients previously treated with BCRi therapy
(either idelalisib or ibrutinib), some of whom had unknown
mutation status. The ERG concluded that the study popu-
lations did not directly conform to those specified in the
licensed indication or in the NICE scope. Outcomes
reported included overall response rate (ORR), duration of
response, progression-free survival (PFS) and overall sur-
vival (OS); adverse events were reported for the pooled
population of all three studies, as well as separately for
each study. The median PFS was 41.4 and 27.2 months
among patients in the M12-175 and M13-982 trials,
respectively, whereas the median PFS was not reached in
the M14-032 trial. Some results were designated academic
in confidence and cannot be reported here. The submission
provided a de novo partitioned survival cost-effectiveness
model with three health states: pre-progression, post-pro-
gression and dead. Transition probabilities between health
states were estimated using Weibull models for PFS and
OS. The ERG judged the model structure to be appropriate.
Venetoclax was compared with best supportive care (BSC)
in patients with or without del(17p)/TP53 mutation status,
and with palliative care (PC). To populate the del(17p)/
TP53 venetoclax arm, the submission pooled del(17p)/
TP53 patients from all three studies and fitted Weibull
models for PFS and OS. PFS and OS models for non-
del(17p)/TP53 venetoclax patients were obtained by
applying hazard ratios (HRs) to the del(17p)/TP53 OS and
PFS models, derived using Cox’s regression analysis
comparing del(17p)/TP53 and non-del(17p)/TP53 patients
pooled from the M14-032 and M12-175 studies. The ERG
expressed reservations about the company’s pooling pro-
cedure, but acknowledged its expedience given the small
evidence base. For the BSC comparator arm, the
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submission used the rituximab? placebo arm from a ran-
domised controlled trial comparing idelalisib? rituximab
versus placebo? rituximab (‘study 116’). Weibull regres-
sion data for OS and PFS were taken from the idelalisib
STA (ID764) submitted by Gilead to NICE. The ERG
considered the use of the study 116 rituximab arm to be
inconsistent with the licensed indication for venetoclax
because these patients had neither not responded to nor
were inappropriate for BCRi therapy, being eligible to be
randomised to idelalisib. Another difficulty was the
requirement for a technical correction in survival analysis
because of considerable switching from rituximab to ide-
lalisib. The ERG considered that post-progression survival
of patients from the idelalisib arm of study 116 provided a
more appropriate representation of BSC since these
patients had not responded to BCRi therapy, consistent
with venetoclax’s licensed indication. For PC, the company
submission used data from the UK CLL Forum. The
company’s base-case analysis indicated that venetoclax
was clinically effective, but the resulting incremental cost-
effectiveness ratios (ICERs) for del(17p)/TP53 (£39,940/
quality-adjusted life-year [QALY] gained) and non-
del(17p)/TP53 (£47,370/QALY gained) patients were well
above the NICE threshold of £20,000–30,000/QALY. The
ERG identified two errors in the implementation of the
company’s parametric models—one related to the imple-
mentation of HRs, and the other to the derivation of the
Weibull shape parameters obtained from the Gilead ide-
lalisib submission. The ERG made plausible adjustments to
the company’s base-case and corrected errors, resulting in a
reduced estimate of the cost effectiveness of venetoclax in
non-del(17p)/TP53 and del(17p)/TP53 indications; in the
ERG’s preferred base case, using post-progression survival
of patients in the idelalisib arm of study 116 as the BSC
comparator, deterministic ICERs were higher than the
company’s base-case for both indications: £57,476/QALY
gained for del(17p)/TP53 and £77,779/QALY gained for
non-del(17p)/TP53. The NICE Appraisal Committee’s
preliminary recommendation was that venetoclax used
within its licensed indication should not be recommended
for use in the National Health Service (NHS). In response
to the preliminary recommendation, the company submit-
ted new analyses; however, at a subsequent appraisal
committee meeting, the original recommendation was
upheld and the committee concluded there were large
uncertainties around the clinical effectiveness of veneto-
clax and BSC, and that under the committee’s preferred
assumptions, the ICERs were higher than those generally
considered cost effective, even when end-of-life criteria
were taken into account. The company submitted further
evidence, and the final guidance recommended venetoclax
for use with the Cancer Drugs Fund for the two populations
in this technology appraisal.
Key Points for Decision Makers
Identifying credible comparisons for single-arm
(uncontrolled) trials presents considerable challenges
to the National Institute for Health and Care
Excellence (NICE) appraisal process, particularly
when naive comparisons are presented.
Given the uncertainties inherent in uncontrolled
comparisons and the potential for bias, the appraisal
process can be expected to closely scrutinise
comparisons selected for company submissions.
Venetoclax has been recommended for use within
the Cancer Drugs Fund as an option for treating
chronic lymphocytic leukaemia for patients with a
17p deletion/TP53 mutation who have not responded
to, or have been deemed unsuitable for, a B-cell
receptor pathway inhibitor, or without a 17p
deletion/TP53 mutation who have not responded to
both chemoimmunotherapy and B-cell receptor
pathway inhibitor therapy.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) is an independent body that appraises existing and
new medical interventions, issuing guidance on their use
within the National Health Service (NHS). Historically,
NICE has assessed both the clinical and economic evidence
within either a single technology appraisal (STA), for a
single technology in a single indication, or in a multiple
technology appraisal (MTA), for more than one technology
or for one technology in more than one indication [1].
Latterly, NICE has relied on the STA process, with some
STAs becoming more complex as a consequence, in terms
of numbers of comparisons or indications. This paper
summarises AbbVie’s clinical effectiveness and cost-ef-
fectiveness submission for use of its product venetoclax,
within its licensed indication, for the treatment of chronic
lymphocytic leukaemia (CLL), together with a description
of the critique of the submitted evidence undertaken by the
Evidence Review Group (ERG) appointed for this STA
(Warwick Evidence), and a brief resume of the develop-
ment of NICE guidance.
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2 Decision Problem
CLLmanifests as theprogressive accumulationof lymphocytes
in the blood, bone marrow and lymphatic tissue. According to
theCLL International Prognostic Index (CLL-IPI) published in
2016 [2], five major independent risk factors impact on the
survival of patients following a diagnosis ofCLL.TheCLL-IPI
scores these risk factors as follows: 17p deletion [del(17p])/
TP53 (deleted/mutated) = 4; immunoglobulin heavy-chain
variable-region (IGVH) not mutated = 2; b2-microglobu-
lin[3.5 mg/L = 2; clinical stage (Rai I–VI or Binet B–
C) = 1; and age[65 years = 1. To estimate an individual’s
prognostic risk, the scores are summed; summed scores of 0–1
are categorised as low risk, 2–3 as intermediate risk, 4–6 as high
risk, and 7–10 as very high risk.
Venetoclax is an orally administered inhibitor of B-cell
lymphoma-2 (Bcl-2), an anti-apoptotic protein overex-
pressed in approximately 95% of CLL patients. Together
with B-cell receptor (BCR) signalling, targeted by BCR
inhibitor (BCRi) drugs such as idelalisib and ibrutinib, Bcl-
2 represents an important element in CLL pathogenesis.
The NICE scope for this STA requested clinical and cost-
effectiveness evidence for venetoclax, within its licensed
indication, compared with standard therapy without vene-
toclax. The anticipated marketing license specified two
indications for venetoclax in CLL:
1. for the treatment of CLL in the presence of the
del(17p) or TP53 mutation in adult patients who are
unsuitable for or have not responded to a BCRi; and
2. for the treatment of CLL in the absence of the del(17p)
or TP53 mutation in adult patients who have not
responded to both chemoimmunotherapy and a BCRi.
3 Submitted Evidence and Evidence Review
Group (ERG) Critique
3.1 Clinical Evidence
The company conducted a literature search and systematic
review that yielded three uncontrolled studies providing
relevant outcome and safety evidence for CLL patients
who received venetoclax. These were single-arm, com-
pany-sponsored trials identified as M13-982 [3] (a multi-
centre international study), M14-032 [4] (a multicentre US
study) and M12-175 [5] (a multicentre dose-ranging safety
assessment study in the US and Australia). The three study
populations were similar in terms of sex, ethnicity and
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, but they differed on age, del(17p)/TP53
chromosomal aberration status, and prior BCRi therapy.
Study M13-982 was a single-arm study in 158 relapsed/
refractory (R/R) CLL patients with the del(17p)/TP53
chromosomal abnormality; a small proportion had received
previous BCRi therapy, the proportion of patients unsuit-
able for BCRi was not reported, and a small number of
patients were treatment-naive [3]. Study M14-032 was a
two-group uncontrolled study of venetoclax in 105 patients
after they had received previous BCRi therapy; the two
groups comprised patients who had received ibrutinib and
idelalisib, respectively [4]. Study M14-032 included simi-
lar proportions of patients with and without del(17p)/TP53
aberration status, most of whom had received prior
chemoimmunotherapy. Study M12-175 evaluated the
safety and efficacy of venetoclax in 67 patients with R/R
CLL or small lymphocytic lymphoma (SLL); a substantial
majority of patients had no previous BCRi therapy. This
study included a mix of patients with and without the
del(17p)/TP53 aberration [5]. The evidence is largely based
on patient populations outside the UK, and the generalis-
ability to the UK population is unclear. Table 1 sum-
marises the baseline characteristics of the three studies, as
presented in the company’s submission. None of the trials
reported disease stage at study entry.
In all three studies, venetoclax was administered orally
and once daily in a stepwise weekly dose ramp-up schedule
over 5 weeks to reach 400 mg daily, followed by 400 mg
daily until disease progression or unacceptable toxicity.
Overall response rate was the primary outcome in
studies M13-982 and M14-328, and a secondary outcome
in study M12-175; safety/adverse effects was the primary
outcome in study M12-175 and a secondary outcome in
studies M13-982 and M14-328; and overall survival (OS)
and progression-free survival (PFS) were additional sec-
ondary outcomes in all three studies. Health-related quality
of life was measured in studies M13-982 and M14-382, but
not in study M12-175.
The company’s submission presented a trial-by-trial
narrative description of outcome results. The median PFS
was 41.4 and 27.2 months among patients in the M12-175
and M13-982 trials, respectively, whereas the median PFS
was not reached in the M14-032 trial. In addition, 86.5% of
patients in the M13-982 trial, and 88.1% of patients in the
prior ibrutinib arm and 95.2% of patients in the prior ide-
lalisib arm in the M14-032 trial, were alive after
12 months. The other results were designated academic in
confidence (AIC) or commercial in confidence (CIC) and
cannot be reported here. A number of outcomes of rele-
vance to the decision problem were not fully reported in the
company submission for some studies (e.g. time to pro-
gression [TTP], European Organisation for Research and
Treatment of Cancer [EORTC] QLQ-C30, EORTC QLQ-
CLL16, and EuroQoL 5 dimensions 5 levels [EQ-5D-5L]).
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The ERG considered that the company had successfully
identified the available clinical outcomes and safety evi-
dence for patients receiving venetoclax in the treatment of
R/R CLL. Within the limits of their study design, the three
included studies were judged to be of good quality. How-
ever, in the context of the STA decision problem, the ERG
found what it considered to be serious deficiencies in the
submitted evidence:
1. None of the included studies enrolled a population
matching the specifications detailed in the licensed
indications. In particular, patients’ status regarding
previous chemoimmunotherapy was unclear, studies
M12-175 and M13-982 failed to satisfy requirements
about receiving or being unsuited for previous BCRi
therapy, and studies M14-032 and M12-175 failed to
satisfy a licensed specification for the del(17p)/TP53
chromosomal abnormality. This resulted in the com-
pany undertaking an ad hoc combination of study
subgroups in order to develop the outcome estimates
required to implement the cost-effectiveness analysis
for the two indications.
2. No comparator evidence was available from the
studies and the submitted clinical effectiveness section
did not identify any other sources of such evidence
(this was undertaken in the cost-effectiveness submis-
sion). As a consequence, estimates of effectiveness
(venetoclax vs. comparator) were restricted to the cost-
effectiveness section of the submission.
3. The studies were relatively small and of relatively
short duration, resulting in substantial uncertainties
associated with venetoclax outcomes, in particular in
the time-to-event outcomes (OS and PFS) needed for
cost-effectiveness analysis.
4. Almost all outcome results were designated AIC, and
the ERG was unable to check the consistency of the
data that were presented because it had not been
published in peer review; there was an inevitable lack
of transparency.
Table 1 Summary of key baseline characteristics of venetoclax studies
Main cohort
[n = 107]
Safety expansion
[n = 51]
Ibrutinib failure
[n = 43]
Idelalisib failure
[n = 21]
Safety expansion
[n = 41]
400 mg analysis set
[n = 67]
Males 70 (65.4) 29 (56.9) 33 (76.7) 15 (71.4) 27 (65.9) 52 (77.6)
White 103 (97.2) 49 (96.1) 40 (93.0) 19 (90.5) 39 (95.1) NR
AgeC 65 years 61 (57.0) 31 (60.8) 26 (60.5) 15 (71.4) 18 (43.9) 35 (52.2)
17p deletion
Present 72 (67.3) 44 (86.3) 21 (48.8) 2 (9.5) 20 (48.8) 14 (20.9)
Absent 2 (1.9) 1 (2.0) NR NR NR 40 (59.7)
Indeterminate 6 (5.6) 1 (2.0) NR NR NR 4 (6.0)
TP53 mutation
Present 61 (57.0) 32 (62.8) 15 (34.9) 1 (4.8) 11 (26.8) 14 (20.9)
Absent 17 (15.9) 9 (17.7) NR NR NR 37 (55.2)
Indeterminate 6 (5.6) 1 (2.0) NR NR NR 0
IGVH status
Present 8 (7.5) 5 (9.8) 4 (9.3) 2 (9.5) 11 (26.8) NR
Absent 28 (26.2) 17 (33.3) NR NR NR NR
Binet stage at diagnosis
A 35 (32.7) 10 (19.6) 0 (0) 2 (9.5) 0 (0) 27 (40.3)
B 24 (22.4) 5 (9.8) 0 (0) 4 (19.1) 1 (2.4) 4 (6.0)
C 18 (16.8) 3 (5.9) 1 (2.3) 0 (0) 1 (2.4) 5 (7.5)
ECOG score
0 42 (39.3) NR 13 (30.2) 5 (23.8) 16 (39.0) 31 (46.2)
1 56 (52.3) NR 27 (62.8) 14 (66.7) 22 (53.7) 34 (50.8)
2 9 (8.4) NR 3 (7.0) 2 (9.5) 3 (7.3) 0
Data are expressed as n (%)
Percentages were calculated by the ERG using the sample size as the denominator; where percentages do not total 100, this is due to missing data
(although the ERG notes that by including missing data, the total sample size for staging in M14 is 109 rather than 105); percentages in the
company submission were calculated using non-missing data
NR not reported, ECOG Eastern Cooperative Oncology Group, ERG Evidence Review Group, IGVH immunoglobulin heavy-chain variable-
region
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3.2 Cost-Effectiveness Evidence
The submission provided a de novo partitioned-survival
economic model comparing venetoclax with best support-
ive care (BSC) or with palliative care (PC). The model had
three health states: pre-progression, post-progression and
dead. The model operated a 28-day cycle length and had a
lifetime horizon. The ERG judged the model structure to be
appropriate to the available evidence for the decision
problem—it was logical and appeared to capture two
important features of the disease (PFS and OS); the cycle
length (28 days) was sufficiently short to allow accurate
modelling of changes over short time periods. The per-
spective, time horizon and discount rates followed NICE
recommendations, and were appropriate to the decision
problem.
The populations modelled in the submission were as
follows: Indication 1: Patients with R/R CLL who had the
del(17p)/TP53 aberration and whose disease had pro-
gressed after treatment with a BCRi; Indication 2: Patients
with R/R CLL who lacked the del(17p)/TP53 aberration
and whose disease had progressed after treatment with both
chemoimmunotherapy and a BCRi. Patients in the vene-
toclax and BSC arms started in the progression-free health
state, while patients in the PC arm started in the progressed
disease health state.
Quality-of-life values for the progression-free health
state were sourced using EQ-5D-5L from two venetoclax
studies [3, 4] and a systematic review on health-related
quality of life conducted by the company. Post-progression
utility values were obtained from the systematic review. In
their base-case, the company assumed that the utility value
for del(17p)/TP53 and non-del(17p)/TP53 patients was the
same and did not apply a quality-of-life decrement asso-
ciated with adverse events.
Considerable challenges were faced in populating the
model. These stemmed from the non-comparative nature of
the venetoclax studies, the lack of conformity in their
populations to the licensed indications, their small size, and
their short duration relative to the model time horizon. The
submission attempted to manage these difficulties, First, by
pooling studies or study subgroups to increase patient
numbers and produce populations conforming more closely
to the licensed requirements; second, by using Weibull
models for PFS and OS to extrapolate to the lifetime
horizon and to generate transition probabilities between
health states; and third, by identifying what was considered
appropriate BSC and PC comparator populations that
provided adequate PFS and OS data. Although statistical
uncertainty may be reduced by pooling, the clinical and
statistical validity of the simple combination of study
patients may be questioned; however, it is acknowledged
that because of the mixed populations in these small
venetoclax trials, pooling may be expedient for the eco-
nomic analysis.
To populate the venetoclax arm for indication 1, the
submission pooled the del(17p)/TP53 subgroups from
M12-175 and M14-032 with patients from the M13-982
study (all of whom carried the del(17p)/TP53 aberration).
The resulting pooled population comprised only approxi-
mately half of the patients who had experienced previous
BCRi therapy; no information was available regarding
unsuitability for BCRi treatment, therefore the pooled
population failed to fully meet the licensed requirements
for indication 1. Weibull parametric models for OS and
PFS were derived using the pooled population.
To populate the venetoclax arm for indication 2, the
submission derived OS and PFS hazard ratios (HRs)
comparing non-del(17p)/TP53 with del(17p)/TP53, and
applied these to the Weibull models of OS and PFS for
indication 1 so as to generate Weibull models of OS and
PFS for indication 2. To obtain the required HRs, the
submission pooled del(17p)/TP53 patients from M14-032
with those from M12-175 to get a del(17p)/TP53 popula-
tion, and pooled non-del(17p)/TP53 patients from M14-
032 and M12-175 to get a non-del(17p)/TP53 population.
These pooled groups were compared as if they were two
arms of a single study, using Cox regression to obtain the
required HRs. The company pooling procedures are sum-
marised in Fig. 1.
The resulting OS and PFS Weibull models for indication
2 failed to fully meet the licensed requirements for indi-
cation 2 in terms of BCRi prior therapy since they are
contingent on the curves generated for indication 1, which
were derived from a population that substantially had not
received prior BCRi therapy. Furthermore, the analysis for
indication 2 involves some double counting of patients
since the del(17p)/TP53 patients from the M12-175 and
M14-032 studies contribute not only to the indication 1
curve but also to the HR estimation modifying it.
Rather than combine subgroups of patients from M14-
032 and M12-175 and then use the combinations as though
each was a single study, the ERG’s preferred procedure
was to obtain an HR [non-del(17p)/TP53 vs. del(17p)/
TP53] for each study and then pool the estimates using
standard random effects meta-analysis. This produced a
smaller HR for OS than the company’s method, and was
therefore less favourable to venetoclax for non-del(17p)/
TP53 OS relative to OS of any comparator.
The company applied the HRs for Weibull models of OS
and PFS incorrectly. This was because the HRs were raised
to the power of the shape parameter before being used as a
multiplier for the Weibull scale parameter (see Supple-
mentary Appendix). Since the shape parameters were
greater than unity, the effect of this error was to inflate the
performance of venetoclax for OS and PFS in indication 2;
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however, the effect was small because shape parameters
were only slightly larger than unity and the HRs were not
large. Because the submission adopted the same procedure
for OS and PFS in their BSC comparator, and because the
shape parameters were erroneously large for BSC (see
Supplementary Appendix), the inflation of OS and PFS in
the company’s BSC comparator for indication 2 was more
substantial.
For the BSC comparator arm, the submission selected
the placebo? rituximab arm from ‘study 116’, a double-
blind, randomised controlled trial comparing idelalis-
ib? rituximab versus placebo? rituximab [6]. Weibull
regression data for OS and PFS were taken from the ide-
lalisib STA submitted by Gilead to NICE [7]; this allowed
the use of more mature data than that available in the
published version of the study [6]. The ERG considered the
use of the study 116 rituximab arm to be inappropriate and
inconsistent with the licensed indication for venetoclax,
because these patients had neither not responded to BCRi
therapy, since they had not received it, nor were they
judged inappropriate for BCRi therapy since they were
eligible to be randomised to idelalisib. Another difficulty
was the requirement for a technical correction to the sur-
vival analysis because of the substantial crossover in the
rituximab arm to idelalisib treatment. The ERG considered
that post-progression survival of patients from the idelal-
isib arm of study 116 provided a more appropriate repre-
sentation of BSC since these patients had not responded to
BCRi therapy and were thus more consistent with the
venetoclax licensed indications.
To generate Weibull models of OS and PFS in BSC
patients with the del(17p)/TP53) abnormality (indication
1), the company made use of Weibull regression parame-
ters available from the idelalisib STA submission, which
included regression values for 17p deletion status and for
IGVH status (see Supplementary Appendix) [7]. In the
ERG‘s opinion, the Weibull shape parameter was applied
incorrectly (see Supplementary Appendix). To generate the
Weibull model’s OS and PFS for BSC patients lacking the
del(17p)/TP53) abnormality (indication 2), the submission
applied the HRs it had derived for the comparison of non-
del(17p)/TP53) versus del(17p)/TP53) in venetoclax
patients. In the ERG’s opinion, it is questionable that the
same HRs would hold across treatments with different
mechanisms of action. Since the idelalisib submission
provided the Weibull regression values for 17p deletion
status, the ERG’s preferred modelling of the non-17p
deletion BSC arm employed this parameter rather than an
HR developed under venetoclax treatment, as used by
AbbVie.
For the PC comparator the company submission pro-
posed patients and data from the UK CLL Forum [8]. The
selected PC population received no active intervention,
and, although older, they matched reasonably well with the
venetoclax study populations on known variables in the
company submission; important prognostic variables
identified by the CLL IPI study were not recorded (IGVH
mutation status, microglobulin, and disease stage). The
proposed PC survival data strongly suggested the presence
of two quite distinct populations with a very different risk
of death. The company was unable to find a satisfactory
parametric fit for PC survival data and was unable to model
the two indications separately. In the opinion of the ERG,
the problematical construction of the PC population, the
likelihood that two distinct subgroups were present, the
lack of a good parametric fit for model extrapolation, the
lack of correspondence between survival of the PC group
and that of BCRi failures in other studies, and the inability
to distinguish between non-del(17p)/TP53 and del(17p)/
TP53 patients, rendered economic analysis of this PC
comparator unsustainable. Furthermore, the company sub-
mission assumed BSC and PC to be competing treatments,
2 POOLED  
non-del(17p)/TP53 
M13-980 
N = 152 
del(17p)/TP53 
M14-032      
  N = 97 
3 POOLED 
del(17p)/TP53 
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N = 56
del(17p)/TP53 
Cox regression to 
obtain HR 
Apply HR to del(17p)/TP53 model to 
obtain model for non-del(17p)/TP53 
non-del(17p)/TP53 del(17p)/TP53  non-del(17p)/TP53
2 POOLED  
 del(17p)/TP53 
Fig. 1 Company submission
pooling procedures. del(17p)
with 17p deletion, non-del(17p)
without 17p deletion, HR hazard
ratio, N sample size
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whereas the ERG considers that BSC and PC would rep-
resent pathways of care for different (although overlap-
ping) patient populations.
The costs of venetoclax treatment were provided by the
company. Venetoclax treatment was assumed to continue
until disease progression or toxicity, with the treatment
effect persisting for up to 20 years. For BSC, patients
received treatment (rituximab or rituximab? high-dose
methylprednisolone) for six cycles only, and for patients in
the PC arm, there was no active treatment. These costs
were obtained from the British National Formulary [9]. The
model also included costs for adverse events, routine care
and terminal care, and for treatment of tumour lysis syn-
drome with rasburicase. All costs were presented in
2014/2015 prices.
The company’s revised base-case economic analysis
indicated that venetoclax provided additional quality-ad-
justed life-years (QALYs), but at an additional cost. For
del(17p)/TP53 patients whose disease had progressed after
a BCRi, or for whom a BCRi was unsuitable, the incre-
mental cost-effectiveness ratio (ICER) was £39,940 per
QALY gained, and for non-del(17p)/TP53 patients whose
disease had progressed after both chemoimmunotherapy
and a BCRi, the ICER was £47,370 per QALY gained. The
deterministic ICERs for venetoclax compared with BSC
exceeded the usual norms accepted by NICE as suitable for
reimbursement (£20,000–£30,000/QALY). In sensitivity
analyses, these estimates were most influenced by the
modelling of PFS and OS for indication 1, and by the HRs
[for del(17p)/TP53 vs. non-del(17p)/TP53] for indication 2.
In critiquing the company‘s economic analysis, the ERG
introduced several changes to the model inputs. The major
change implemented by the ERG was to abandon the
company models of OS and PFS for BSC based on the
rituximab arm of study 116 and to instead substitute the
post-progression survival of the idelalisib? rituximab arm
of study 116. For the PC comparator, the ERG considered
that the data used in the company submission had too many
deficiencies for it to sustain a reasonable comparison for
use in cost-effectiveness analysis. Additional changes
involved correcting the application of HRs, correcting the
starting age and proportion of males for patients with non-
del(17p)/TP53, reducing the utility value for the PFS health
state, and including disutility values for adverse events.
When the ERG’s preferred inputs were applied to the
company’s base-case, the resulting ICERs for venetoclax
versus BSC for indications 1 (£55,476/QALY gained) and
2 (£77,779/QALY gained) increased substantially. In sen-
sitivity analysis, the ERG employed post-progression sur-
vival after failure of ibrutinib as the BSC comparator,
taking data from Jansen’s submission to NICE for the STA
‘Ibrutinib for treating relapsed or refractory CLL’ [10].
Again, this delivered an ICER (£61,120/QALY gained)
higher than the company’s base-case ICER for indication 1.
3.3 Conclusions of the ERG Review
The three trials sourced for evidence in the company sub-
mission included patients who did not meet the decision
problem. Evidence that better met the decision problem
was based on post hoc subgroup combinations from single-
arm studies with heterogeneous populations. The absence
of direct or formal indirect comparisons means that the true
treatment benefit of venetoclax is uncertain. The company
submission selected one arm of an unrelated RCT to
approximate the comparator of BSC, however the ERG
considers that the population in that arm is unsuitable as a
comparator group. Caution is therefore necessary in the
interpretation of the submitted results. Even though the
company’s economic model was appropriate, its short-
comings were mainly due to the lack of an appropriate
comparator(s). The BSC group chosen in the company
submission was a misfit for the decision problem and for
the licensed indications. The PC comparator data used in
the company submission had too many deficiencies for it to
sustain a reasonable comparison for use in cost-effective-
ness analysis.
4 Development of National Institute for Health
and Care Excellence Guidance
In developing guidance, the NICE Appraisal Committee’s
preliminary recommendation was that venetoclax used
within its licensed indication should not be recommended
for use in the NHS. With regard to the BSC comparator, the
committee suggested that the comparator population
selected by the ERG more closely matched the population
that would be offered venetoclax than that selected in the
company submission. However, the committee expressed
concern that whatever the source of comparator data used,
the comparisons would be naive and potentially subject to
bias. The committee preferred the ERG’s utility value for
the PFS health state. The company submission value based
on pooled data from the venetoclax trials was considered
implausible since patients with CLL would not be expected
to have a higher quality of life than people of the same age
without disease. The committee concluded that it preferred
the ERG’s base-case, which included disutility for adverse
events, and updated the costs of some adverse events
included in the company submission.
In response to the preliminary recommendation, the
company submitted new analyses. In a second appraisal
meeting, the committee concluded there were large
uncertainties around the clinical effectiveness of
Venetoclax for Treating Chronic Lymphocytic Leukaemia
venetoclax and BSC, and that under the committee’s pre-
ferred assumptions, the ICERs were higher than those
generally considered cost effective, even when end-of-life
criteria were taken into account. In their final guidance
published in November 2017 [11] NICE recommended
venetoclax for use with the Cancer Drugs Fund for patients
with indications 1 and 2.
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